Neusignal Therapeutics Raises JPY 5.32 Billion in Series B Funding

To the Members of the Press

June 30, 2026

Neusignal Therapeutics, Inc.

Neusignal Therapeutics, Inc. (Headquarters: Chuo-ku, Tokyo; Representative Director: Tatsu Arimoto; hereinafter referred to as "NTX"), a company developing Alzheimer's disease therapeutics originating from Tohoku University, announced today that it has successfully raised approximately JPY 5.32 billion in total funding for this round through a third-party allotment of shares to the investors listed below, as well as a grant from AMED's "Drug Discovery Venture Ecosystem Strengthening Project."

Purpose and Use of Funds

Utilizing funds raised in Series A, NTX initiated a physician-led clinical trial (single ascending dose study in healthy adults) for its investigational drug NTX-083 at the University of Tokyo Hospital in February 2025, and reported the completion of observation for all subjects in September of the same year. Furthermore, a corporate-led clinical trial (multiple ascending dose study in healthy adults) for NTX-083 commenced in November 2025, with observation for all subjects completed in March 2026. Both studies confirmed high safety and tolerability, with no significant adverse events reported in safety assessments. Additionally, it was revealed that NTX-083 demonstrated an excellent pharmacokinetic profile in both single and multiple ascending dose administrations. These trials progressed faster than originally planned.

Based on these achievements, NTX plans to utilize the funds raised in this Series B round to initiate a Phase 1b study in patients with Alzheimer's disease in the United States later this year. The company will also proceed with talent acquisition and other initiatives with the aim of forming business partnerships with global pharmaceutical companies thereafter.

Investors (in no particular order)

New Investors:

Angel Bridge, Inc. (Co-Lead Investor), DCI Partners, Inc. (Co-Lead Investor), Nissay Capital Co., Ltd., Red Capital, Inc., Gokin Capital Co., Ltd.

Existing Investors:

Fast Track Initiative, Inc., Keio Innovation Initiative, Inc., Mitsubishi UFJ Capital Co., Ltd., SMBC Venture Capital Co., Ltd., FFG Venture Business Partners, Inc., Japan Venture Capital Co., Ltd.

Background

NTX, a startup focused on commercializing seeds from Tohoku University, is dedicated to developing a groundbreaking therapeutic for Alzheimer's disease, a condition affecting an increasing number of people worldwide. In recent years, new drugs that may slow the progression of Alzheimer's disease have emerged. While expectations for these new drugs are high, discussions are ongoing regarding new challenges, including the difficulty of treatment management, high medical costs, and the selection of appropriate patients considering the balance of benefits and risks. NTX believes its investigational drug has the potential to be a revolutionary therapy that addresses these challenges, aiming to deliver it to patients and their families suffering from the disease.

(In no particular order)

Comment from Angel Bridge, Inc.

Dementia is an area with extremely high unmet medical needs, where effective treatments are still lacking. NTX-083, developed by NTX, is an innovative small molecule compound with a novel mechanism of action, conceived by Professor Moriguchi through in-depth research into the mechanisms of existing drugs. We believe it has the potential to be a game-changer in dementia treatment. Backed by solid scientific evidence and a management team with extensive clinical development experience, Angel Bridge will provide its full support to help NTX-083 reach patients and their families worldwide as quickly as possible.

(Yutaro Kosai, Managing Partner / Hikaru Ihara, Senior Associate)

Comment from DCI Partners, Inc.

NTX possesses extremely high potential to create innovative pharmaceuticals based on original seeds for intractable diseases like Alzheimer's disease, which have very high unmet medical needs. Through this funding, we expect them to further advance global development in the United States and become a blockbuster drug in the future, offering a new treatment option for patients worldwide. We will provide proactive support to help achieve business success and deliver new drugs to patients as quickly as possible.

(Hiroki Narita, Representative Director / Shoma Tanaka, Director)

Comment from Fast Track Initiative, Inc.

Since our initial investment in NTX through the FTI Fund No. 3, we have continuously supported the development of its key pipeline, NTX-083. We are delighted to celebrate the company's achievement of raising approximately JPY 5.32 billion (including the AMED "Drug Discovery Venture Ecosystem Strengthening Project" grant) in its Series B round.

Following the previous funding, the NTX team has made significant progress in the clinical development of NTX-083, and the confirmation of high safety and tolerability in healthy individuals is a major advancement. Patient dosing is now set to begin, with results expected by the end of next fiscal year. We anticipate that this investigational drug will demonstrate excellent efficacy. We will continue to provide maximum support, in collaboration with other investors, to ensure the swift global launch of this novel AD therapeutic.

(Makoto Takeuchi, Director)

Comment from Keio Innovation Initiative, Inc.

NTX has consistently achieved milestones at an astonishing pace, including the completion of domestic clinical trials and the submission of an IND application to the US FDA. We are very pleased to have made a third additional investment from the KII Fund No. 3 Impact as NTX embarks on the extremely important step of initiating the US Phase 1b clinical trial, which will showcase the potential of NTX-083 to the world. Together with our existing investors who have accompanied them thus far, and our strong new investors who have joined this round, we will form a solid one team and provide our full support to deliver NTX-083 to patients worldwide as quickly as possible.

(Yuto Torii, Principal)

Comment from Nissay Capital Co., Ltd.

NTX-083, developed by NTX, is a candidate therapeutic drug for "Alzheimer's disease," for which no effective treatment has yet been established. It is a small molecule drug with a different mechanism of action from existing drugs. We believe that if this candidate drug is approved, it will help save more patients, and we are pleased to offer our modest support. We look forward to its launch as soon as possible.

(Naoki Akiyama, Representative Director)

Comment from Mitsubishi UFJ Capital Co., Ltd.

We continue to hold NTX, a developer of innovative small molecule drugs for Alzheimer's disease, in high regard and are pleased to have the opportunity to provide additional support for this development. The confirmation of safety and tolerability in the Phase 1 corporate trial in Japan since our previous investment is highly encouraging, and we believe they are making steady progress towards market launch. Clinical trials in patients are now scheduled to commence in the United States, and as MUFG, we will continue to provide strong support to deliver this treatment to patients worldwide as quickly as possible.

(Hiroo Kubo, Deputy General Manager, Life Science Department)

Comment from Red Capital, Inc.

Dementia remains a disease area with high unmet medical needs, and there is a strong demand for the creation of new treatment options. NTX is addressing this critical challenge based on its unique scientific insights. We expect that the research and development efforts, driven by the unified dedication of the management and R&D teams, will be further accelerated through this funding. Red Capital will continue to provide full support to deliver innovative therapies to patients as quickly as possible.

(Maiko Katadae, Representative Director & Managing Partner)

Comment from FFG Venture Business Partners, Inc.

We are very pleased to have been given the opportunity to make an additional investment following the previous round.

We believe this investigational drug, as a small molecule compound with a novel mechanism of action, has great potential to become a first-line treatment for Alzheimer's disease, an area with extremely high unmet medical needs. Furthermore, the favorable results obtained in the clinical trials conducted since Series A have further increased our expectations.

We sincerely hope that this investigational drug will contribute globally as an innovative solution to improve the quality of life for many suffering patients and their families, address societal challenges such as economic losses due to caregiving burdens, and reduce high medical costs. We will continue to provide maximum support.

(Yusho Furumi, Investment Manager, Investment Department)

Comment from SMBC Venture Capital Co., Ltd.

We are very grateful for the continued opportunity to make an additional investment.

While new antibody drugs for Alzheimer's disease have been approved, it remains an area with strong unmet medical needs. Our investigational drug has a different mechanism of action from existing approved drugs, and if successful, it is expected to be a game-changer in Alzheimer's disease therapeutics.

Although it is a challenging field to develop, we believe that with the strong leadership of the NTX members, the Phase 1 corporate trial (multiple ascending dose study) has been successfully completed, bringing us closer to delivering it to patients. We will continue to provide our full support to help solve societal challenges.

(Masakazu Komahashi, General Manager, Third Investment Sales Department)

Comment from Japan Venture Capital Co., Ltd.

We are very pleased to have invested in NTX again. We sincerely hope that through the development of NTX's Alzheimer's disease therapeutic with a novel mechanism of action, we can contribute to patients and their families suffering from this serious illness worldwide. We expect that the company's management and employees, who possess world-class knowledge and experience in this field, will bravely tackle challenging development and achieve significant results. NVCC will continue to provide our full support.

(Yuyang Liu, Venture Capitalist / Yuko Kitaoka, Senior Partner)

Comment from Gokin Capital Co., Ltd.

Neusignal Therapeutics is advancing groundbreaking drug discovery research that is expected to achieve both "improvement of current symptoms" and "inhibition of disease progression" in Alzheimer's disease, which has been difficult to date. Due to its uniqueness and strong team capabilities, the development is progressing smoothly with the support of many stakeholders, and we have judged that there is a high possibility of commercialization, leading us to invest this time. We will continue to provide support so that the company's therapeutic can reach patients as soon as possible.

(Yuki Kihara, Senior Manager)

About Neusignal Therapeutics, Inc.

・Date of Establishment: April 1, 2022

・Location: 3-11-5 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023

・Representative: Tatsu Arimoto

・Business Activities: Research and development of therapeutics for dementia and psychiatric disorders, discovery of drug seeds for brain diseases

・Official Website: https://neusignal-tx.com/

End